Zafar N Aliyev1, Nadir A Aliyev. 1. Narcological Dispensary of Ministry of Health of Azerbaijan Republic, Azerbaijan Republic.
Abstract
AIMS: The aim of this study was to compare the efficacy and safety of valproate (Depakine-Chrono) versus placebo for the treatment of acute alcohol hallucinosis. METHODS: 10 days' randomized, double-blind, parallel study was conducted; 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis were randomized to valproate (Depakine-Chrono) 3000 mg/day (n = 20) or placebo (n = 20). The primary efficacy measure was the Clinical Global Improvement (CGI) and the Positive and Negative Syndrome Scale (PANSS), subscale for hallucinosis. RESULTS:Valproate-treated patients demonstrated a greater improvement than placebo-treated patients in CGI (P < 0.001) and PANSS subscale for verbal hallucinosis (P < 0.001). CONCLUSION:Valproate is effective in the treatment of acute hallucinosis and is generally well tolerated.
RCT Entities:
AIMS: The aim of this study was to compare the efficacy and safety of valproate (Depakine-Chrono) versus placebo for the treatment of acute alcohol hallucinosis. METHODS: 10 days' randomized, double-blind, parallel study was conducted; 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis were randomized to valproate (Depakine-Chrono) 3000 mg/day (n = 20) or placebo (n = 20). The primary efficacy measure was the Clinical Global Improvement (CGI) and the Positive and Negative Syndrome Scale (PANSS), subscale for hallucinosis. RESULTS:Valproate-treated patients demonstrated a greater improvement than placebo-treated patients in CGI (P < 0.001) and PANSS subscale for verbal hallucinosis (P < 0.001). CONCLUSION:Valproate is effective in the treatment of acute hallucinosis and is generally well tolerated.
Authors: Jean-Michel Azorin; Charles L Bowden; Ricardo P Garay; Giulio Perugi; Eduard Vieta; Allan H Young Journal: Neuropsychiatr Dis Treat Date: 2010-03-24 Impact factor: 2.570
Authors: Pasquale Caponnetto; Marilena Maglia; Graziella Chiara Prezzavento; Concetta Pirrone Journal: Int J Environ Res Public Health Date: 2022-02-25 Impact factor: 3.390